Pretreatment of RANKL-primed RAW 264.7 precursors with pharmacological inhibitor of MEK1/2, PD98059 attenuated ERK1/2 activation both at 30 and 60 min after exposure to prostate cancer CM (Figure 6B). Here, MAPK3 is linked to prostate carcinoma.